The Institute of Hepatology, University College London, London, UK.
Liver Int. 2010 Apr;30(4):521-6. doi: 10.1111/j.1478-3231.2009.02194.x. Epub 2009 Dec 22.
Cell-mediated immune responses play an important role in the control of tumour growth. CD4 and CD8 T cells recognise tumour antigens presented via major histocompatibility complex molecules of antigen presenting cells and develop into effector cells with the ability to identify and kill tumour cells. Here, we re-examine the adaptive immune response to tumour antigens expressed by hepatocellular carcinoma (HCC) and discuss approaches that could be applied in future T-cell-based immunotherapy schedules to induce a potent and effective antitumour immunity. Moreover, we discuss cytotoxic T lymphocyte and Th1 responses to tumour antigens in patients with HCC and evaluate the effects of conventional treatments on antitumour T-cell responses.
细胞介导的免疫应答在肿瘤生长的控制中起着重要作用。CD4 和 CD8 T 细胞识别通过抗原呈递细胞的主要组织相容性复合体分子呈递的肿瘤抗原,并发育成具有识别和杀死肿瘤细胞能力的效应细胞。在这里,我们重新审视了肝癌 (HCC) 表达的肿瘤抗原的适应性免疫反应,并讨论了未来可应用于基于 T 细胞的免疫治疗方案以诱导有效抗肿瘤免疫的方法。此外,我们还讨论了 HCC 患者的细胞毒性 T 淋巴细胞和 Th1 反应,并评估了常规治疗对抗肿瘤 T 细胞反应的影响。